Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Qin, Hua; Zhao, Andong

doi:10.1007/s13238-020-00738-2

Cited by 111 publications

(97 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A signi cant proportion of COVID-19 patients have mild symptoms, such as fever, muscle ache, cough, shortness of breath and fatigue, and about half of patients are with no obvious symptoms [2,3]. However, some severe cases with severe pneumonia can develop into acute respiratory distress syndrome (ARDS), pulmonary edema, or multiple organ dysfunction syndrome(MODS), hence leading to a high mortality [4][5][6]. Although many patients have mild symptoms, they may suddenly progress to ARDS, septic shock, or even MODS [7].…”

Section: Introductionmentioning

confidence: 99%

Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Liu

Mao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background：Coronavirus disease 2019 (COVID-19), a highly infectious disease, has been rapidly spreading all over the world and posted a great threat to global public health. Patients diagnosed with severe or critical cases have a poor prognosis. Hence, it is crucial for us to identify potential severe or critical cases early, and give timely treatments for the targeted patients. In the clinical practice of treating COVID-19 patients, we have observed that the neutrophil-to-lymphocyte ratio (NLR) of severe patients is higher than that in mild patients. We performed this systematic review and meta-analysis to evaluate the predictive values of NLR on disease severity and mortality in COVID-19 patients. Methods: We searched PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang databases to identify eligible studies (up to August 11, 2020). Two authors independently screened studies and extracted data. The methodological quality of the included studies was assessed by Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).Results: Thirteen studies involving 1579 patients reported the predictive value of NLR on disease severity. The pooled sensitivity (SEN), specificity (SPE) and area under curve (AUC) were 0.78 (95% CI 0.70-0.84), 0.78 (95% CI 0.73-0.83) and 0.85 (95% CI 0.81-0.88), respectively. Ten studies involving 2967 patients reported the predictive value of NLR on mortality. The pooled SEN, SPE and AUC were 0.83 (95% CI 0.75-0.89), 0.83 (95% CI 0.74-0.89) and 0.90 (95% CI 0.87-0.92), respectively. Conclusions: NLR has good predictive values on disease severity and mortality in COVID-19 patients. Evaluating NLR can help clinicians identify potentially severe cases early, conduct early triage and initiate effective management in time, which may reduce the overall mortality of COVID-19. Moreover, we can better allocate scarce medical resources in this unprecedented time. Trial registration: This meta-analysis was prospectively registered on PROSPERO database (Registration number: CRD42020203612).

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Liu

Mao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…To date, as previously discussed, the available data regarding MSC administration in pre-clinical and clinical viral infections are still scarce and inconsistent in the literature. Preclinical models of acute lung injury, acute respiratory distress syndrome (ARDS), viral hepatitis, HIV infection, and viral pneumonia have been evaluated in the last years [87,111,112,114]. The safety of this MSC-based therapy has also been demonstrated in early-stage clinical studies, although in relatively small patient cohorts with different MSC sources and study designs [87,111,112,114].…”

Section: Future Directions Of Msc-based Therapies For Covid-19 and Otmentioning

confidence: 99%

“…Preclinical models of acute lung injury, acute respiratory distress syndrome (ARDS), viral hepatitis, HIV infection, and viral pneumonia have been evaluated in the last years [87,111,112,114]. The safety of this MSC-based therapy has also been demonstrated in early-stage clinical studies, although in relatively small patient cohorts with different MSC sources and study designs [87,111,112,114]. To date there are no established priming/preconditioning protocols designed to improve the therapeutic effect of MSCs to target viral infections [115,116].…”

Section: Future Directions Of Msc-based Therapies For Covid-19 and Otmentioning

confidence: 99%

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Rocha

Oliveira

Noronha

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied.

show abstract

“…Recent studies have investigated the therapeutic effects of MSCs in the novel coronavirus 2 (SARS-CoV-2)-induced ARDS and organ failure [109][110][111]. In a pilot trial, Leng et al performed intravenous transplantation of ACE2overexpressing MSCs into seven patients with COVID-19 pneumonia.…”

Section: Genetically Modified Mscs For the Treatment Of Acute Lung Inmentioning

confidence: 99%

Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness

Varkouhi

Monteiro

Tsoporis

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Critical illnesses including sepsis, acute respiratory distress syndromes, ischemic cardiovascular disorders and acute organ injuries are associated with high mortality, morbidity as well as significant health care system expenses. While these diverse conditions require different specific therapeutic approaches, mesenchymal stem/stromal cell (MSCs) are multipotent cells capable of self-renewal, tri-lineage differentiation with a broad range regenerative and immunomodulatory activities, making them attractive for the treatment of critical illness. The therapeutic effects of MSCs have been extensively investigated in several pre-clinical models of critical illness as well as in phase I and II clinical cell therapy trials with mixed results. Whilst these studies have demonstrated the therapeutic potential for MSC therapy in critical illness, optimization for clinical use is an ongoing challenge. MSCs can be readily genetically modified by application of different techniques and tools leading to overexpress or inhibit genes related to their immunomodulatory or regenerative functions. Here we will review recent approaches designed to enhance the therapeutic potential of MSCs with an emphasis on the technology used to generate genetically modified cells, target genes, target diseases and the implication of genetically modified MSCs in cell therapy for critical illness.

show abstract

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Cited by 111 publications

References 133 publications

Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness

Contact Info

Product

Resources

About